Bayer's Shares Tread Water as Finerenon Data Brings Pipeline Hope While Roundup Settlement Looms

Bayer's stock hovers near its 200-day moving average amid promising Finerenon trial results and a looming $7.25 billion Roundup settlement deadline.

Bayer closed out last week with its stock hovering at €35.95, barely above the 200-day moving average of €35.80 — a technical foothold that looks increasingly precarious. The modest level belies a week packed with developments that could reshape the company's trajectory: a promising kidney drug study on one side, and the ticking clock of a multibillion-dollar legal settlement on the other.

The pharmaceutical division delivered the more encouraging news. On June 5, Bayer unveiled results from the Phase-III FIND-CKD trial, showing that Finerenon — marketed as Kerendia — slowed kidney function decline in patients with non-diabetic chronic kidney disease. The eGFR slope difference versus placebo came in at 0.7 ml/min/1.73 m² per year, while a composite cardiorenal secondary endpoint dropped by 23%. The data ran simultaneously at the ERA congress and in the New England Journal of Medicine, giving the company maximum scientific visibility.

Bayer also released the pre-specified INFINITY pooled analysis, combining FIND-CKD with the earlier FIDELIO-DKD and FIGARO-DKD studies across 14,574 patients. The analysis showed a 24% reduction in the primary renal endpoint for Finerenon and a 20% drop in hospitalization for heart failure or cardiovascular death. Results were published in The Lancet. The breadth of the dataset — three completed Phase-III trials — gives regulators an unusually robust basis for evaluation. Bayer plans to submit the new indication to health authorities, though it offered no timeline for filing or decision.

Yet the market has not rushed to reprice the shares. Kerendia is already one of the few growth drivers in a pharma division that reported €4.249 billion in first-quarter 2026 sales, flat year-on-year as gains from Nubeqa and Kerendia offset patent losses on older products like Xarelto. The real question is whether the expanded indication will translate into a meaningful revenue uplift — and that depends on regulatory speed and pricing, neither of which is certain.

What is holding the stock back is the familiar legal overhang. On June 4, the opt-out deadline passed in Missouri for a Roundup settlement that could cost up to $7.25 billion. The deal is designed to cover both current and future glyphosate claims, but its viability hinges on how many plaintiffs walk away. CEO Bill Anderson warned that “it could take several weeks” to get a clear picture. A final approval hearing is set for July, and Bayer retains the right to pull the plug if too many claimants opt out. The settlement has already drawn formal opposition: lawyers in Missouri filed an objection on May 21, branding it “grossly inadequate and unfair.”

Meanwhile, the Durnell case before the Supreme Court carries even more systemic risk. The justices are weighing whether state court verdicts can stand when the EPA considers glyphosate safe. A ruling in Bayer’s favour would effectively wipe out roughly 65,000 pending cases. JPMorgan analyst Richard Vosser estimates the decision could affect about 80% of active litigation. Anderson expressed confidence that Bayer could materially reduce its legal burden this year, ruling outcome or not.

The financial strain is real. Bayer is spending around €5 billion on litigation this year. Net financial debt rose to €32.5 billion in the first quarter, while free cash flow turned negative to minus €2.3 billion. The new CFO, Judith Hartmann, took over the finance role on June 1, succeeding Wolfgang Nickl. She brings experience from Sandbrook Capital, Engie and Bertelsmann, and arrives at a moment when the company must manage cash carefully while navigating multiple legal deadlines.

Beyond the courtroom, the pipeline holds other levers. In May, the FDA accepted Bayer’s filing for Asundexian, granting priority review. The drug aims to prevent secondary strokes after certain ischemic events, backed by positive Phase-III data from the OCEANIC-STROKE study. Japan and China are also reviewing the application. Management continues to target adjusted operating earnings of €9.4 billion to €9.9 billion for the full year.

The near-term action revolves around two events. The Supreme Court is expected to rule by the end of June. Before that, the opt-out count from Missouri could move the stock. For now, the 200-day line at €35.80 is the technical floor — hold it, and the recovery story stays alive. Break it, and the legal gravity pulls the shares lower.